Skip to content
Subscriber Only

J&J’s Risperdal Sales May Have Violated Pact, Witness Said

A Johnson & Johnson unit’s marketing of its Risperdal antipsychotic drug to doctors treating mentally ill children may have violated the drugmaker’s agreement with Texas, a state official testified.

A push by J&J’s Janssen unit to increase Risperdal prescriptions for children and adolescents before 2006 may have broken the drugmaker’s promises to “comply with all state and federal laws” in exchange for having the drug covered by the Texas Medicaid program, Billy Milwee, the state Medicaid director, told a jury today. The U.S. Food and Drug Administration didn’t approve Risperdal for any pediatric use until 2006.